Eloralintide
LY3841136
An investigational once-weekly selective amylin receptor agonist, advancing to Phase 3. It is not approved for any use.
- Half-life
- Not established
- Out of system
- —
- Route
- Subcutaneous
- Level
- Advanced
What Eloralintide is used for
- Selective amylin receptor agonism, without GLP-1 activity
- 9.5%-20.1% mean weight loss across dose arms at 48 weeks vs 0.4% on placebo (Phase 2, 263 adults)
- Reported improvements in waist circumference, blood pressure, lipids, glycaemic control and inflammatory markers
How it's typically used
Trial range: 1, 3, 6 or 9 mg subcutaneously once weekly, or escalation to 9 mg, per study protocol. Not approved — trial participation is the only route.
What to watch for
- Investigational; Phase 2 complete and Phase 3 announced, not approved anywhere
- The 20% figure is the top dose arm — the lowest arm reached 9.5%, and the spread is the point
- Not obtainable outside a clinical trial
- Long-term safety and durability are still unknown
Common questions
- How is Eloralintide taken?
- Eloralintide is typically administered by the subcutaneous route. Trial range: 1, 3, 6 or 9 mg subcutaneously once weekly, or escalation to 9 mg, per study protocol. Not approved — trial participation is the only route.
- What are the risks of Eloralintide?
- Investigational; Phase 2 complete and Phase 3 announced, not approved anywhere The 20% figure is the top dose arm — the lowest arm reached 9.5%, and the spread is the point Not obtainable outside a clinical trial Long-term safety and durability are still unknown
About GLP-1 & weight loss
- What they are
- Incretin analogues — GLP-1 and dual/triple agonists. They slow stomach emptying and act on appetite centres in the brain, so you eat less without white-knuckling it.
- How they're run
- One subcutaneous shot a week for most, on the same day each week. Doses climb in steps every four weeks; that slow titration is what keeps side effects tolerable.
- What to watch
- Nausea, constipation, and reflux are near-universal in the first month. Muscle is lost alongside fat unless you keep protein high and keep lifting. Tell any surgeon or anaesthetist you are on one.
Other glp-1 & weight loss
Peptid AI is an educational and self-tracking tool — not a medical service, and not a vendor. Nothing here is medical advice, a prescription, or an endorsement. Doses reflect what is commonly reported in research literature; they are not recommendations. Many compounds listed are experimental, not approved for human use, and/or controlled substances that are illegal to possess without a prescription in many countries. Always consult a qualified physician before starting, changing, or stopping any protocol.